Clinical Trial Update: Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

The Phase 2 randomized trial evaluating pembrolizumab with and without Exablate MRgFUS for recurrent glioblastoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Glioblastoma | Phase 2 | Status: WITHDRAWN